Physician profile
David R Bloom
NPI 1417005737
$1,537.95
in general payments reported to CMS, 2019-2025
26 companies · $21.99 in 2025
The $21.99 reported for 2025 was less than what a typical Sports Medicine (Family Medicine) provider received nationally (typical 2025 total: $113).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $334 · 2020: $374 · 2021: $597 · 2022: $173 · 2023: $38.23 · 2025: $21.99.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $60.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $60.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $260.38 | 2019-2022 | |
| Amarin Pharma, INC. | $221.29 | 2019-2021 | |
| Abiomed | $170.95 | 2021 | |
| Novo Nordisk INC | $150.14 | 2019-2022 | |
| Lilly USA, LLC | $68.01 | 2019-2021 | |
| Sanofi Pasteur INC. | $65.04 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $57.57 | 2019-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $54.71 | 2022 | |
| Allergan, INC. | $54.51 | 2020 | |
| Teva Pharmaceuticals USA, INC. | $49.34 | 2019-2020 | |
| Daiichi Sankyo INC. | $42.32 | 2019-2021 | |
| Antares Pharma, INC. | $42.09 | 2019-2020 | |
| Bard Peripheral Vascular, INC. | $37.44 | 2022-2023 | Venclose Maven Catheter |
| Medtronic USA, INC. | $27.70 | 2019 | |
| Vanda Pharmaceuticals INC. | $24.78 | 2020 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceuticals, INC. | $23.98 | 2021 | |
| Alfasigma USA, INC. | $23.77 | 2021 | |
| Exact Sciences Corporation | $21.99 | 2025 | Cologuard Collection Kit |
| Genentech USA, INC. | $21.92 | 2021 | |
| Eisai INC. | $21.36 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $21.13 | 2021 | |
| Novartis Pharmaceuticals Corporation | $19.00 | 2022 | |
| Pfizer INC. | $18.71 | 2023 | |
| Gilead Sciences, INC. | $15.19 | 2020 | |
| Amgen INC. | $14.59 | 2021 | |
| Bardy Diagnostics, INC. | $10.04 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Bloom listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.